Crinetics Pharmaceuticals (CRNX) Assets Average (2018 - 2026)

Crinetics Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Assets Average fell 9.6% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 9.6% YoY), while the FY2025 annual figure was $1.3 billion, up 23.72% from the prior year.
• Assets Average was $1.3 billion for Q1 2026 at Crinetics Pharmaceuticals, up from $1.2 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2025 to a low of $303.6 million in Q2 2023.
• Historically, Assets Average has averaged $794.8 million across 5 years, with a median of $806.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Assets Average dropped 19.57% in 2023, then jumped 215.13% in 2024.
• A 5-year view of Assets Average shows it stood at $368.5 million in 2022, then soared by 73.24% to $638.4 million in 2023, then soared by 85.76% to $1.2 billion in 2024, then decreased by 2.09% to $1.2 billion in 2025, then rose by 8.84% to $1.3 billion in 2026.
• The last three Assets Average figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.